Gilead Sciences/GILD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Ticker
GILD
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Foster City, United States
Employees
18,000
Website
www.gilead.com
Gilead Sciences Metrics
BasicAdvanced
$86B
Market cap
176.74
P/E ratio
$0.39
EPS
0.22
Beta
$3.02
Dividend rate
4.40%
Dividend yield
Price and volume
Market cap
$86B
Beta
0.22
Dividend rate
$3.02
Financial strength
Current ratio
0.98
Quick ratio
0.783
Long term debt to equity
147.935
Total debt to equity
147.935
Dividend payout ratio (TTM)
789.69%
Interest coverage (TTM)
10.25%
Management effectiveness
Return on assets (TTM)
10.62%
Return on equity (TTM)
2.39%
Valuation
Price to earnings (TTM)
176.74
Price to revenue (TTM)
3.12
Price to book
4.88
Price to tangible book (TTM)
-5.99
Price to free cash flow (TTM)
10.84
Dividend yield (TTM)
4.40%
Growth
Revenue change (TTM)
1.51%
Earnings per share change (TTM)
-91.21%
3-year revenue growth
2.40%
3-year earnings per share growth
17.45%
3-year dividend per share growth
3.17%
What the Analysts think about Gilead Sciences
Analyst Ratings
Majority rating from 32 analysts.
Gilead Sciences Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$6.7B
-6.02%
Net income
-$4.2B
-392.09%
Profit margin
-62.38%
-410.81%
Gilead Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.34
$2.29
$1.72
-$1.32
-
Expected
$1.64
$1.92
$1.76
-$1.49
$1.59
Surprise
-18.42%
19.44%
-2.24%
-11.59%
-
Gilead Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $86B as of July 03, 2024.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 176.74 as of July 03, 2024.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of July 03, 2024, the dividend rate is $3.02 and the yield is 4.4%. Gilead Sciences has a payout ratio of 789.69% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment date is unconfirmed.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Gilead Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.